Literature DB >> 26176400

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

Mizuki Nishino1, Lynette M Sholl, F Stephen Hodi, Hiroto Hatabu, Nikhil H Ramaiya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26176400      PMCID： PMC4539956          DOI： 10.1056/NEJMc1505197

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

2.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Authors:  Naiyer A Rizvi; Julien Mazières; David Planchard; Thomas E Stinchcombe; Grace K Dy; Scott J Antonia; Leora Horn; Hervé Lena; Elisa Minenza; Bertrand Mennecier; Gregory A Otterson; Luis T Campos; David R Gandara; Benjamin P Levy; Suresh G Nair; Gérard Zalcman; Jürgen Wolf; Pierre-Jean Souquet; Editta Baldini; Federico Cappuzzo; Christos Chouaid; Afshin Dowlati; Rachel Sanborn; Ariel Lopez-Chavez; Christian Grohe; Rudolf M Huber; Christopher T Harbison; Christine Baudelet; Brian J Lestini; Suresh S Ramalingam
Journal:  Lancet Oncol       Date:  2015-02-20       Impact factor: 41.316

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

5.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors:  Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544
  5 in total
  132 in total

1.  Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.

Authors:  Mizuki Nishino; Emily S Chambers; Curtis R Chong; Nikhil H Ramaiya; Stacy W Gray; J Paul Marcoux; Hiroto Hatabu; Pasi A Jänne; F Stephen Hodi; Mark M Awad
Journal:  Cancer Immunol Res       Date:  2016-02-10       Impact factor: 11.151

2.  Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.

Authors:  Frances Rickard; Catherine Hyams; Andrew T Low
Journal:  BMJ Case Rep       Date:  2018-05-07

3.  Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.

Authors:  Sawsan Rashdan; John D Minna; David E Gerber
Journal:  Lancet Respir Med       Date:  2018-06       Impact factor: 30.700

4.  Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.

Authors:  Mizuki Nishino; Lynette M Sholl; Mark M Awad; Hiroto Hatabu; Philippe Armand; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2018-04-05       Impact factor: 11.151

Review 5.  Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease.

Authors:  Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis
Journal:  Physiol Rev       Date:  2019-10-01       Impact factor: 37.312

Review 6.  Cardiotoxicity of Immune Checkpoint Inhibitors.

Authors:  Lili Zhang; Maeve Jones-O'Connor; Magid Awadalla; Daniel A Zlotoff; Paaladinesh Thavendiranathan; John D Groarke; Alexandra-Chloe Villani; Alexander R Lyon; Tomas G Neilan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-06-08

7.  Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion.

Authors:  Vanessa A Reed; Naiyer Rizvi
Journal:  Oncologist       Date:  2019-03-21

Review 8.  Imaging of Cancer Immunotherapy: Current Approaches and Future Directions.

Authors:  Mizuki Nishino; Hiroto Hatabu; F Stephen Hodi
Journal:  Radiology       Date:  2018-11-20       Impact factor: 11.105

Review 9.  Gaps in nutritional research among older adults with cancer.

Authors:  Carolyn J Presley; Efrat Dotan; Enrique Soto-Perez-de-Celis; Aminah Jatoi; Supriya G Mohile; Elizabeth Won; Shabbir Alibhai; Deepak Kilari; Robert Harrison; Heidi D Klepin; Tanya M Wildes; Karen Mustian; Wendy Demark-Wahnefried
Journal:  J Geriatr Oncol       Date:  2016-07-05       Impact factor: 3.599

Review 10.  Toxicity management of immunotherapy for patients with metastatic melanoma.

Authors:  Helena Linardou; Helen Gogas
Journal:  Ann Transl Med       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.